0000000001100542

AUTHOR

Emma Renard

showing 4 related works from this author

Design of Bimodal Ligands of Neurotensin Receptor 1 for Positron Emission Tomography Imaging and Fluorescence-Guided Surgery of Pancreatic Cancer

2020

International audience; Neurotensin receptor 1 (NTSR1) is overexpressed in most human pancreatic ductal adenocarcinomas. It makes it an attractive target for the development of pancreatic cancer imaging agents. In this study, we sought to develop a bimodal PET-fluorescent imaging agent capable of specifically targeting these receptors. Starting from the structure of a known NTSR1 agonist, a series of tracers was synthesized, radiometalated with gallium-68 and evaluated in vitro and in vivo, in mice bearing an AsPC-1 xenograft. PET imaging allowed us to identify the compound [ 68 Ga]Ga-NODAGA-Lys(Cy5**)-AEEAc-[Me-Arg 8 , Tle 12 ]-NT(7-13) as the one with the most promising biodistribution pr…

Neurotensin receptor 1positron emission tomographydual-modality[SDV]Life Sciences [q-bio]Gallium RadioisotopesAcetatesLigands01 natural sciencesHeterocyclic Compounds 1-RingMice03 medical and health sciencesgallium-68Cell Line TumorPancreatic cancerDrug DiscoverymedicineAnimalsHumansReceptors Neurotensin[CHIM]Chemical SciencesPancreatic carcinomaPancreasNeurotensinFluorescent Dyes030304 developmental biology0303 health sciencesmedicine.diagnostic_testChemistryOptical Imagingmedicine.diseaseFluorescence0104 chemical sciencesPancreatic Neoplasms010404 medicinal & biomolecular chemistrySurgery Computer-AssistedPositron emission tomographyPositron-Emission TomographyCancer researchMolecular MedicineFemalefluorescence-guided surgery
researchProduct

Positron Emission Tomography Imaging of Neurotensin Receptor-Positive Tumors with 68 Ga-Labeled Antagonists: The Chelate Makes the Difference Again

2021

Neurotensin receptor 1 (NTS1) is involved in the development and progression of numerous cancers, which makes it an interesting target for the development of diagnostic and therapeutic agents. A small molecule NTS1 antagonist, named [177Lu]Lu-IPN01087, is currently evaluated in phase I/II clinical trials for the targeted therapy of neurotensin receptor-positive cancers. In this study, we synthesized seven compounds based on the structure of NTS1 antagonists, bearing different chelating agents, and radiolabeled them with gallium-68 for PET imaging. These compounds were evaluated in vitro and in vivo in mice bearing a HT-29 xenograft. The compound [68Ga]Ga-bisNODAGA-16 showed a promising biod…

0303 health sciencesBiodistributionNeurotensin receptor 1medicine.diagnostic_testChemistrymedicine.disease3. Good health03 medical and health scienceschemistry.chemical_compound0302 clinical medicinePositron emission tomographyIn vivo030220 oncology & carcinogenesisDrug DiscoverymedicineCancer research[INFO.INFO-IM]Computer Science [cs]/Medical ImagingMolecular MedicineAdenocarcinoma[CHIM]Chemical SciencesNeurotensin receptorReceptorComputingMilieux_MISCELLANEOUS030304 developmental biologyNeurotensin
researchProduct

Site-Specific Dual-Labeling of a VHH with a Chelator and a Photosensitizer for Nuclear Imaging and Targeted Photodynamic Therapy of EGFR-Positive Tum…

2021

Simple Summary Variable domains of heavy chain only antibodies are small proteins that can be used for tumor imaging and therapy upon conjugation of functional groups. As frequently used random conjugation techniques can decrease binding to the target of interest, site-specific conjugation of these functional groups is preferred. Here, we optimized site-specific conjugation of both a chelator for binding of a radiometal and a photosensitizer to epidermal growth factor receptor (EGFR) binding VHH 7D12. We characterized this dual-labeled VHH for nuclear imaging and targeted photodynamic therapy of EGFR-expressing tumors. Abstract Variable domains of heavy chain only antibodies (VHHs) are valu…

Cancer ResearchFluorescence-lifetime imaging microscopyBiodistribution[SDV.IB.IMA]Life Sciences [q-bio]/Bioengineering/Imagingmedia_common.quotation_subjectmedicine.medical_treatmentPhotodynamic therapyvariable domain of heavy chain only antibodies (VHH); site-specific conjugation; dual-labeling; nuclear imaging; photodynamic therapy[SDV.CAN]Life Sciences [q-bio]/Cancer[CHIM.THER]Chemical Sciences/Medicinal Chemistrylcsh:RC254-282Article030218 nuclear medicine & medical imaging03 medical and health sciencesTumours of the digestive tract Radboud Institute for Health Sciences [Radboudumc 14]0302 clinical medicineAll institutes and research themes of the Radboud University Medical CenterIn vivoduallabelingmedicineTumours of the digestive tract Radboud Institute for Molecular Life Sciences [Radboudumc 14]PhotosensitizerInternalizationmedia_commonnuclear imagingChemistrysite-specific conjugationlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens3. Good healthOncologyphotodynamic therapy030220 oncology & carcinogenesisUrological cancers Radboud Institute for Health Sciences [Radboudumc 15]dual-labelingBiophysicsvariable domain of heavy chain only antibodies (VHH)A431 cellsEx vivoCancers
researchProduct

Design of molecular imaging and theranostic agents for the detection and targeted therapy of cancers

2020

Despite significant advances in cancer detection and treatment, cancer is now the second leading cause of death worldwide. The aim of this thesis project was to design and optimize imaging agents for the diagnosis and/or therapy of various cancers.The first axis of this thesis focused on the development of a bimodal PET/fluorescence imaging agent capable of targeting neurotensin NTS1 receptors overexpressed in certain cancers. PET imaging would allow efficient detection of tumors and their metastases, while fluorescence imaging would facilitate the evaluation of tumor margins during surgery. Several compounds were synthesized, labelled with gallium-68 and studied in preclinical studies in a…

Fluorescence-Guided surgeryNeurotensine[CHIM.ORGA]Chemical Sciences/Organic chemistryImagerie moléculaireChirurgie assistée par lfuorescenceMolecular imagingImagerie nucléaireThérapie photodynamique[CHIM.ORGA] Chemical Sciences/Organic chemistryNuclear imagingPhotodynamic therapyNeurotensinCancer
researchProduct